Compare PRGO & OPY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRGO | OPY |
|---|---|---|
| Founded | 1887 | 1881 |
| Country | Ireland | United States |
| Employees | N/A | 2947 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2013 | 1996 |
| Metric | PRGO | OPY |
|---|---|---|
| Price | $11.78 | $114.96 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $19.33 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 54.3K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 10.16% | 0.64% |
| EPS Growth | N/A | ★ 104.71 |
| EPS | N/A | ★ 13.04 |
| Revenue | $800,000.00 | ★ $1,638,071,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.02 | N/A |
| P/E Ratio | ★ N/A | $8.68 |
| Revenue Growth | N/A | ★ 14.35 |
| 52 Week Low | $9.23 | $54.98 |
| 52 Week High | $28.44 | $114.50 |
| Indicator | PRGO | OPY |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 82.16 |
| Support Level | $9.24 | $82.75 |
| Resistance Level | $15.08 | N/A |
| Average True Range (ATR) | 0.51 | 3.89 |
| MACD | 0.26 | 2.15 |
| Stochastic Oscillator | 95.35 | 91.71 |
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.